SCHEDULE: State Street Discloses 5.5% Stake in Altimmune

State Street Corporation has reported beneficial ownership of 5.5% of Altimmune Inc.'s common stock as of March 31, 2026.

Summary

• State Street Corporation has filed a Schedule 13G, indicating its beneficial ownership of Altimmune Inc. common stock.
• As of March 31, 2026, State Street Corporation beneficially owns 7,145,550 shares of Altimmune Inc. common stock.
• This ownership represents 5.5% of the total class of securities.
• The filing indicates shared power to vote and dispose of these shares, with 7,012,433 shares having shared voting power and 7,145,550 shares having shared dispositive power.
• State Street Corporation is classified as a holding company and its subsidiaries involved in this filing include SSGA FUNDS MANAGEMENT, INC., STATE STREET GLOBAL ADVISORS EUROPE LIMITED, and STATE STREET GLOBAL ADVISORS TRUST COMPANY.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It indicates significant passive investment by a major financial institution, which can be a positive signal, but it does not provide operational or financial performance data for Altimmune Inc. itself.

Positives

• State Street Corporation's investment indicates confidence in Altimmune Inc. from a major financial institution.
• The 5.5% stake suggests a significant, though not controlling, interest, potentially leading to increased institutional attention and stability.

Negatives

• The filing is a standard Schedule 13G, which typically indicates passive investment and does not inherently signal positive or negative performance for Altimmune Inc.

Risks

• As a Schedule 13G filing, it primarily reports ownership levels and does not detail specific risks related to Altimmune Inc.'s business operations or financial health.

Future Outlook

This filing is a disclosure of ownership and does not contain forward-looking statements or guidance from Altimmune Inc.

Industry Context

StockSavvy.ai notes that Schedule 13G filings from large financial institutions like State Street Corporation are common for tracking institutional investment trends. A 5.5% stake in a biotechnology company like Altimmune Inc. signifies substantial passive investment, often by asset management arms of major banks, reflecting their assessment of the company's potential without necessarily implying active engagement in management.

Stakeholder Impact

• Shareholders: The increased institutional ownership by a large entity like State Street Corporation may be viewed positively, potentially increasing liquidity and market interest in Altimmune Inc. stock.
• Management: The filing does not directly impact management but signifies a significant passive investor in the company.

Next Steps

• State Street Corporation will continue to hold its shares in Altimmune Inc. and will file amendments to this Schedule 13G if there are any material changes in its beneficial ownership.

Key Dates

Keywords

Altimmune Inc., State Street Corporation, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, SSGA